MediPharm welcomes the news that the United States government is examining the rescheduling of cannabis from Schedule I (drugs with no currently accepted medical use and a high potential for abuse) to Schedule III (drugs with a moderate to low potential for physical and psychological dependence). This is an important step in recognizing the therapeutic potential of cannabinoids and opens up further opportunities for researchers to explore cannabinoid-based treatments.
MediPharm Labs was mentioned in the article below, discussing the impacts of this legislative change.
The US Department of Health and Human Services (HHS) recommendation to reschedule cannabis marks a significant shift in drug policy, untangling decades of prohibition and offering new opportunities for the industry, writes FoxNRTH's Principal, Chris Murray. But there are still a number of questions that need to be answered.
MediPharm Labs stands ready to partner with researchers providing GMP products made in our Health Canada, FDA, and Australian TGA inspected facility for their trials.